NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Christopher D Riemann, MD
Neuracle Genetics, Inc. Medical Director
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Vancouver Coastal Health Research Institute
Vancouver, British Columbia, Canada
- Sunnybrook Ophthalmology and Vision Services
Toronto, Ontario, Canada
- Vitreous Retina Macula Specialists of Toronto
Toronto, Ontario, Canada
- Cincinnati Eye Institute
Cincinnati, Ohio, United States
- Retina Consultants of Texas
Bellaire, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Sept 2023
- Primary completion
- 31 Jan 2026
- Completion
- 31 Jan 2030
- Last update posted
- 20 Jan 2026
- Registered enrollment
- 20
- Registry id
- NCT05984927
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.